Basic information Safety Supplier Related

Flotetuzumab

Basic information Safety Supplier Related

Flotetuzumab Basic information

Product Name:
Flotetuzumab
Synonyms:
  • Flotetuzumab
  • Research Grade Flotetuzumab (DHD72504)
  • Research Grade Flotetuzumab
CAS:
1664355-28-5
MW:
0
Mol File:
Mol File
More
Less

Flotetuzumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Flotetuzumab Usage And Synthesis

Uses

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML)[1][2].

in vivo

Flotetuzumab (0.5-4 μg/kg; intraperitoneal implantation; continuous infusion for 6 d) shows antitumor activity in human peripheral blood mononuclear cells (PBMCs)-reconstituted tumor-bearing mice[1].
Flotetuzumab (0.5 mg/kg; once every 5 d; for 30 d) improves mouse survival and induces T-cell proliferation in mouse NTPL-146 patient-derived xenograft (PDX) model of acute myeloid leukemia (AML)[2].

Animal Model:PBMCs-reconstituted tumor model: NSG/β2m-/- mice intradermally implanted with the KG-1a (AML-M0) cells on day 0 and intraperitoneally injected with human PBMCs on day 1[1]
Dosage:0.5 μg/kg, 1 μg/kg, and 4 μg/kg;
Administration:Peritoneally implantation with mini-osmotic pumps; continuous infusion from days 16 to 22;
Result:Inhibited tumor volume significantly.

References

[1] Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015 May 27;7(289):289ra82. DOI:10.1126/scitranslmed.aaa5693
[2] Barwe SP, et al. Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. J Clin Med. 2022 Feb 28;11(5):1333. DOI:10.3390/jcm11051333

FlotetuzumabSupplier

ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com